Table 1 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

The study assesses demographics of women receiving camizestrant combined with CDK4/6 inhibitors.
Patient profiles include those treated with abemaciclib, palbociclib, or ribociclib for advanced breast cancer.
Baseline characteristics outline the context of therapy for ER+ and HER2− patients.
Findings can inform future treatment strategies in advanced breast cancer management.

Analysis of patient demographics receiving camizestrant with CDK4/6 inhibitors, indicating treatment profiles and baseline characteristics.

Baseline characteristics and patient demographics for camizestrant in combination with abemaciclib, palbociclib, or ribociclib.

No takes yet. Share an insight, caveat, or question.

Baird et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share